CPIX (Cumberland Pharmaceuticals Inc) Net Profit

Corporate emblem and logo of cumberlandpharma.com (CPIX)

Cumberland Pharmaceuticals (CPIX) relies on steady cash flows from hospital drugs, although budget limits and generics constrain pricing power. The company's net operating result is displayed by this GURU.Markets chart, where the latest mark is -0.01. A stable workforce is maintained through transparent bonuses and a corporate culture that attracts experienced regulatory specialists and sales professionals.

CPIX (Cumberland Pharmaceuticals Inc.) Company Net Income history from 07/04/2022 to 10/31/2026

Financial and market metric breakdowns for Cumberland Pharmaceuticals Inc. (CPIX)

- price and consensus price forecast:
Stock Quotes Cumberland Corp|CPIX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Cumberland Corp|CPIX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Cumberland Pharmaceuticals|CPIX - Company Book Value|Market-to-Book Ratio cumberlandpharma.com|CPIX - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Cumberland Pharmaceuticals|CPIX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Cumberland Pharmaceuticals Inc|CPIX - Company Aggregate Debts|Debts to Book Value Cumberland Corp|CPIX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Cumberland Pharmaceuticals|Quick Liquidity Indicator cumberlandpharma.com
- net income and valuation multiples indicators:
CPIX - Net Income
Fundamental valuation:CPIX Cumberland Corp
Flagship merchandise of Cumberland Pharmaceuticals Inc

To assess the sustainability of the Cumberland Pharmaceuticals (CPIX) business model, it is critical to filter out random market noise and one-off transactions that could distort actual returns. The growth in government procurement of Vibativ and the expansion of the GI portfolio must convert into systemic revenue, allowing the company's current profit to determine the true trajectory toward break-even. This indicator aggregates the net financial result, helping investors distinguish fundamental resilience from the risk of overpayment.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Net Profit TBPH (Theravance Biopharma, Inc.)|AQST - Net Income|SCPH: Net Income|TECX - Net Profit|Tonix Pharmaceuticals (TNXP) - Company Net Income|Net Income China SXT Pharmaceuticals, Inc.|EPRX (Eupraxia Pharmaceuticals, Inc.) - Net Profit|Company Net Income BHST|Net Profit EXOZ|ORMP - Company Net Income|Company Net Income Entera Bio ENTX|Final Profit HYFT|ABVC - Company Net Income|QNTM: Company Net Income|FGEN: Net Profit|Telomir Pharmaceuticals Corp (TELO) - Net Profit|Company Net Income Rani Therapeutics Holdings|Company Profit SNYR (Synergy CHC Corporation)|Net Profit RLYB|lexariabioscience.com - Company Profit|Pulmatrix Corp - Net Income|Final Profit PTHL|APM - Company Net Income|Profit After Tax LYRA|IBO: Net Profit|TNF Pharmaceuticals, Inc. - Final Profit|YCBD (cbdMD Inc.) - Net Profit|Net Profit PainReform Corp|Company Net Income Altamira Therapeutics (CYTO)|LIPO (lipella.com) - Final Profit|Company Net Income OptiNose OPTN|PIRS - Net Income|Procaps Group SA - Net Profit|PTPI - Net Profit|QLI: Net Profit|Net Income acelyrin.com|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit